- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03579602
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects who provide voluntary written informed consent, or have it provided by their legally acceptable representative, will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate.
Surgical excision will occur at least 1 hour and no more than 36 hours after tozuleristide administration. Surgery will be performed by a neurosurgeon and the Canvas will be operated by a designated Imaging Operator. Fluorescence of tumor and ambiguous tissue during surgery will be assessed and scored. Biopsy samples of these tumor and ambiguous tissues will be collected for pathology analysis.
All subjects will be monitored for safety during their participation in the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Expanded Access
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Chlidren's Hospital Los Angeles
-
San Francisco, California, United States, 94158
- University of California, San Francisco
-
-
Florida
-
Gainesville, Florida, United States, 32608
- University of Florida Shands Hospital
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Children's Hospital of Michigan
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55102
- Children's Minnesota
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University St. Louis Children's Hospital
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be >1 month and ≤30 years of age at the time of study enrollment
- Subjects must have MRI obtained within 30 days of study enrollment documenting a measurable lesion consistent with a pediatric primary CNS tumor for which maximal safe resection is indicated
- Adequate renal function
- Adequate liver function
Prior therapy: Subjects with prior therapy are eligible provided they have recovered from any acute toxic effects of prior therapy and have sufficient time interval prior to enrollment:
- Radiation therapy: subjects may not have had radiation therapy to the area of tumor planned to be resected within 28 days of study enrollment
- Chemotherapy: at least 14 days from any myelosuppressive chemotherapy (28 days if prior nitrosourea) and if prior chemotherapy, must have an absolute neutrophil count recovery of ≥ 1000/mm3 following count nadir
- Biologic: at least 7 days from any anti-neoplastic biologic agent (at least 3 half-lives since last administration of monoclonal antibodies)
- Immunotherapy: at least 42 days after completion of any cellular immunotherapy, such as CAR-T cell therapy
- Prior surgery for CNS tumors is allowed
- Prior tozuleristide: at least 1 week after prior dose of tozuleristide if previously treated
- Written informed consent must be obtained from the subject or parent or legal guardian prior to the conduct of study activities. Routine clinical tests, e.g., MRI, clinical laboratory studies, may be used for screening requirements. Assent, when appropriate, will be obtained according to institutional guidelines.
- The risks of treatment with tozuleristide during pregnancy have not been evaluated. Female subjects of child-bearing potential must agree not to attempt to become pregnant or undergo in vitro fertilization and, if participating in sexual activity that could lead to pregnancy, must use 2 reliable methods of contraception simultaneously for 30 days after surgery. Male subjects must agree not to attempt to father a child and, if participating in sexual activity that could lead to pregnancy, must use 2 reliable methods of contraception simultaneously for 30 days after surgery if their partner is of child-bearing potential.
Exclusion Criteria:
- Pregnancy and contraception: Subjects who are pregnant or breast-feeding or planning to conceive a child within 30 days are not eligible. Males and females of childbearing potential must agree to use 2 effective forms of contraception from the time of enrollment until 30 days post-surgery
- Subjects with on-going serious medical conditions (poorly controlled asthma, diabetes, heart disease) such that participation in the study could put the subject at increased risk of worsening their condition
- Subjects planned to undergo only a diagnostic biopsy procedure, without intent to resect tissue for therapeutic purposes (e.g., stereotactic pontine biopsy)
- Subjects who in the opinion of the investigator are not willing or able to comply with randomization procedures or other study-required study procedures and observations. Subjects previously enrolled and randomized to Arm 1 (control) are not eligible for re-enrollment unless a second surgery is required by standard of care.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Arm 1 (no tozuleristide)
Subjects randomized to Arm 1 (~9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
|
All subjects enrolled in the study will have their tissue imaged with the Canvas System.
Other Names:
|
EXPERIMENTAL: Arm 2 (tozuleristide treated)
Subjects randomized to Arm 2 (~ 91% of subjects) will be administered tozuleristide at a dose of 15 mg/m^2 at least 1 hour and no more than 36 hours prior to surgery.
They will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
|
All subjects enrolled in the study will have their tissue imaged with the Canvas System.
Other Names:
Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of tozuleristide fluorescence to detect tumor in equivocal (ambiguous) tissue during surgery when imaged with the Canvas system
Time Frame: During surgery (which occurs at least 1 hour post tozuleristide administration)
|
Sensitivity and specificity of tozuleristide imaged with the Canvas system to fluorescently identify tumor in equivocal tissue will be evaluated based on assessments made by the surgeon and imaging operator.
These measures will be compared to the sensitivity and specificity of surgical designation of equivocal tissue without fluorescence.
|
During surgery (which occurs at least 1 hour post tozuleristide administration)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety - number of patients with adverse events
Time Frame: AEs will be collected from day of randomization until Day 8. Subjects will be contacted monthly for up to 3 months post-surgery for safety assessments.
|
Safety will be assessed by physical examination and measurement of vital signs and laboratory safety parameters.
|
AEs will be collected from day of randomization until Day 8. Subjects will be contacted monthly for up to 3 months post-surgery for safety assessments.
|
Extent of resection
Time Frame: At completion of surgery and up to 72 hours post-surgery for MRI assessment. If additional MRIs are obtained within 3 months post-surgery, they will be submitted for central MRI review.
|
Extent of resection will be evaluated by the surgeon and by central review of post-operative magnetic resonance images (MRI).
Extent of resection will be designated in the following categories: gross total resection (GTR; all tumor removed), near total resection (NTR; bulk of tumor removed), sub-total resection (STR; residual tumor present).
|
At completion of surgery and up to 72 hours post-surgery for MRI assessment. If additional MRIs are obtained within 3 months post-surgery, they will be submitted for central MRI review.
|
Concentration of tozuleristide in the blood (pharmacokinetics)
Time Frame: Subjects in Arm 2 only will have blood samples collected at 2 time points: One within 30 minutes after tozuleristide administration and one between 30 minutes and 180 minutes after tozuleristide administration.
|
Tozuleristide concentration in the blood will be analyzed by chemical means and these data will be used to calculate pharmacokinetic parameters.
|
Subjects in Arm 2 only will have blood samples collected at 2 time points: One within 30 minutes after tozuleristide administration and one between 30 minutes and 180 minutes after tozuleristide administration.
|
Performance of the Canvas system
Time Frame: After completion of surgery
|
The surgeon and imaging operator will complete a survey to evaluate the usability of the Canvas during surgery
|
After completion of surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sarah Leary, MD, Seattle Children's Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BB-006
- PNOC012 (OTHER: Pacific Pediatric Neuro-Oncology Consortium)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Central Nervous System Tumor
-
Memorial Sloan Kettering Cancer CenterColumbia University; University of Washington; University of Texas; Rutgers UniversityActive, not recruitingBrain Tumor | Pediatric Cancer | Pediatric Brain TumorUnited States
-
University of Alabama at BirminghamTerminated
-
University of California, San FranciscoCompletedPediatric Brain TumorsUnited States
-
Weill Medical College of Cornell UniversityRecruitingCentral Nervous System Tumor | Pediatric Central Nervous System TumorUnited States
-
Sabine Mueller, MD, PhDWashington University School of Medicine; Nationwide Children's Hospital; Rally...Not yet recruitingPediatric Brain Tumor | Recurrent Pediatric Brain Tumor | Pediatric Supratentorial NeoplasmUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...CNOG-MC001 Collaborative GroupCompletedPediatric Brain Tumor | Malignant Brain Tumor | Tumors, Central Nervous System | Benign Brain TumorChina
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingCentral Nervous System Tumor | Somatic Mutation | Pediatric Central Nervous System Tumor | Discordant TwinUnited States
-
Westfälische Wilhelms-Universität Münsterphotonamic GmbH & Co. KG; medac GmbHRecruitingBrain Tumor, PediatricGermany, Netherlands
-
Sheffield Children's NHS Foundation TrustGE Healthcare; University of SheffieldNot yet recruitingBrain Tumor, Pediatric
-
Washington University School of MedicineNot yet recruitingBrain Tumor, PrimaryUnited States
Clinical Trials on Canvas System
-
Cognoa, Inc.University of Missouri-ColumbiaCompletedChildren18-72 Months With a Suspicion Autistic DisorderUnited States
-
John YuBlaze Bioscience Inc.RecruitingCentral Nervous System TumorUnited States
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom
-
Zahedan University of Medical SciencesUnknownPain, Postoperative Pain Pathologic Processes Postoperative Complications Signs and Symptoms
-
University of British ColumbiaNot yet recruitingPersistent Developmental Stutter | Childhood-Onset Fluency Disorder (Stuttering)